Saudi Regulators Suspend Use Of Avandia; GSK Says Action Not Based On Recent Data

In a new development following recent attention brought by a U.S. Senate Finance Committee report, the Saudi Arabia Food and Drug Authority has suspended the use of GlaxoSmithKline's Avandia (rosiglitazone) for six months while a review is under way